Key facts for NCD 190.29
- Benefit category
- Diagnostic Laboratory Tests
- Effective date
- 11/25/2002
- Implemented 01/01/2003
- Transmittal
- Transmittal 17
- Versions published
- 1
- Lab edit list
- 73 covered ICD-10
- 233 non-covered
TL;DR
NCD 190.29 sets Medicare's national policy for tumor antigen by immunoassay - ca 15-3/ca 27.29 under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy. As a laboratory NCD it carries a national ICD-10 edit list: 73 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 1 procedure code.
Item or service described
Immunoassay determinations of the serum levels of certain proteins or carbohydrates serve as tumor markers. When elevated, serum concentration of these markers may reflect tumor size and grade. This policy specifically addresses the following tumor antigens: CA 15-3 and CA 27.29
Indications and limitations of coverage
Indications
Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy.
CA 15-3 is often medically necessary to aid in the management of patients with breast cancer. Serial testing must be used in conjunction with other clinical methods for monitoring breast cancer. For monitoring, if medically necessary, use consistently either CA 15-3 or CA 27.29, not both.
CA 27.29 is equivalent to CA 15-3 in its usage in management of patients with breast cancer.
Limitations
These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy. The service may be ordered at times necessary to assess either the presence of recurrent disease or the patient's response to treatment with subsequent treatment cycles.
Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).
Text reproduced from the CMS Medicare Coverage Database record for NCD 190.29 version 1. View the original on cms.gov.
Laboratory NCD code lists (October 2026)
Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 73 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.
1 procedure code are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.
| Code | Code set |
|---|---|
| 86300 | CPT (descriptor licensed by AMA) |
What Medicare pays for these tests: 1 of the 1 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $20.81, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.
| Code | CLFS amount | With QW | Pricing |
|---|---|---|---|
| 86300 | $20.81 | — | national payment amount |
The first 40 of 73 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.
| ICD-10-CM | Description | Effective |
|---|---|---|
| C44.1321 | Sebaceous cell carcinoma of skin of right upper eyelid, including canthus | 2018-10-01 |
| C44.1322 | Sebaceous cell carcinoma of skin of right lower eyelid, including canthus | 2018-10-01 |
| C44.1391 | Sebaceous cell carcinoma of skin of left upper eyelid, including canthus | 2018-10-01 |
| C44.1392 | Sebaceous cell carcinoma of skin of left lower eyelid, including canthus | 2018-10-01 |
| C50.011 | Malignant neoplasm of nipple and areola, right female breast | 2015-10-01 |
| C50.012 | Malignant neoplasm of nipple and areola, left female breast | 2015-10-01 |
| C50.019 | Malignant neoplasm of nipple and areola, unspecified female breast | 2015-10-01 |
| C50.021 | Malignant neoplasm of nipple and areola, right male breast | 2015-10-01 |
| C50.022 | Malignant neoplasm of nipple and areola, left male breast | 2015-10-01 |
| C50.029 | Malignant neoplasm of nipple and areola, unspecified male breast | 2015-10-01 |
| C50.111 | Malignant neoplasm of central portion of right female breast | 2015-10-01 |
| C50.112 | Malignant neoplasm of central portion of left female breast | 2015-10-01 |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast | 2015-10-01 |
| C50.121 | Malignant neoplasm of central portion of right male breast | 2015-10-01 |
| C50.122 | Malignant neoplasm of central portion of left male breast | 2015-10-01 |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast | 2015-10-01 |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast | 2015-10-01 |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast | 2015-10-01 |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast | 2015-10-01 |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast | 2015-10-01 |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast | 2015-10-01 |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast | 2015-10-01 |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast | 2015-10-01 |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast | 2015-10-01 |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast | 2015-10-01 |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast | 2015-10-01 |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast | 2015-10-01 |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast | 2015-10-01 |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast | 2015-10-01 |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast | 2015-10-01 |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast | 2015-10-01 |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast | 2015-10-01 |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast | 2015-10-01 |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast | 2015-10-01 |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast | 2015-10-01 |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast | 2015-10-01 |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast | 2015-10-01 |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast | 2015-10-01 |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast | 2015-10-01 |
| C50.529 | Malignant neoplasm of lower-outer quadrant of unspecified male breast | 2015-10-01 |
233 diagnosis codes deny automatically under this NCD; the first 20 are shown.
| ICD-10-CM | Description |
|---|---|
| R99 | Ill-defined and unknown cause of mortality |
| Z00.00 | Encounter for general adult medical examination without abnormal findings |
| Z00.01 | Encounter for general adult medical examination with abnormal findings |
| Z00.110 | Health examination for newborn under 8 days old |
| Z00.111 | Health examination for newborn 8 to 28 days old |
| Z00.121 | Encounter for routine child health examination with abnormal findings |
| Z00.129 | Encounter for routine child health examination without abnormal findings |
| Z00.5 | Encounter for examination of potential donor of organ and tissue |
| Z00.6 | Encounter for examination for normal comparison and control in clinical research program |
| Z00.70 | Encounter for examination for period of delayed growth in childhood without abnormal findings |
| Z00.71 | Encounter for examination for period of delayed growth in childhood with abnormal findings |
| Z00.8 | Encounter for other general examination |
| Z02.0 | Encounter for examination for admission to educational institution |
| Z02.1 | Encounter for pre-employment examination |
| Z02.2 | Encounter for examination for admission to residential institution |
| Z02.3 | Encounter for examination for recruitment to armed forces |
| Z02.4 | Encounter for examination for driving license |
| Z02.5 | Encounter for examination for participation in sport |
| Z02.6 | Encounter for examination for insurance purposes |
| Z02.71 | Encounter for disability determination |
Changed in October 2026
The October 2026 lab NCD release made no change to this NCD's ICD-10-CM list: no code was added, removed or given a new result against January 2026. The last change was in January 2026, when CMS added 2 codes.
Codes on this NCD's list by release: October 2025: 304 · January 2026: 306 · October 2026: 306. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.
Revision history
07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)
07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
For teams evaluating QuickIntell software
Evaluate a coverage-review workflow around NCD 190.29
Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — NCD 190.29
What does NCD 190.29 cover?
Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 190.29 take effect?
The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.
Does a Local Coverage Determination override NCD 190.29?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Which diagnosis codes are covered under NCD 190.29?
The October 2026 laboratory NCD edit list contains 73 ICD-10-CM codes that support tumor antigen by immunoassay - ca 15-3/ca 27.29 (for example C44.1321 Sebaceous cell carcinoma of skin of right upper eyelid, including canthus; C44.1322 Sebaceous cell carcinoma of skin of right lower eyelid, including canthus; C44.1391 Sebaceous cell carcinoma of skin of left upper eyelid, including canthus) and 233 codes that deny. The list applies to 86300.
How often does the lab NCD code list for 190.29 change?
CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.
CMS guidance
Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:
- Complying With Documentation Requirements for Lab Services(MLN909221, )What documentation supports a laboratory claim: the order, the medical necessity and the results.
- Clinical Laboratory Fee Schedule(MLN006818, )How the Clinical Laboratory Fee Schedule is set, including data reporting and the payment determination.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
- Laboratory NCD ICD-10 code lists, October 2026Version October 2026 · effective 2026-10-01 · file 2026400-Initial-ICD10-NCD-Spreadsheet-20260601-508.xlsxSHA-256 ec4361dc65f63432…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.